الفهرس 
NEONATAL JAUNDICEOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Background: One of the most prevalent illnesses in neonates that needs care and treatment is neonatal jaundice. Fenofibrate as a lipid-lowering drug that can enhance bilirubin conjugation and excretion. Previous studies suggest the usefulness of fenofibrate in the treatment of hyperbilirubinemia.
Objective: To evaluate the prophylactic role of fenofibrate in term Neonates with Hyperbilirubinemia.
Patients and Methods: 75 full-term infants with hyper bilirubinemia were included and were divided randomly into 3 groups: Single dose group: 25 full term neonates who received a single oral dose of 10 mg/kg of non- micronized fenofibrate and an oral dose of equivalent amount of distilled. Double dose group: 25 full term neonates who received two oral doses of 10 mg/kg of non - micronized fenofibrate Control group: 25 full term neonates who received two oral doses of equivalent amount of distilled water.
Results: double dose group had the highest percentage of DROP of transcutaneous bilirubin (TCB) starting from 12 to 48 hours after drug intake and highest percentage of DROP of total serum bilirubin (TSB) starting from 12 hour to the 5th day after the drug intake, followed by single dose group. The lowest percentage of DROP of TCB and TSB were reported in the control group. Single dose group and double dose group had significantly lower incidence of need for admission when compared to control group (P=0.009) and need for phototherapy when compared to control group (P=0.009). Double dose group had significantly higher incidence of drug effects when compared to single dose group (P< 0.001), mainly in the form of abdominal distension (P=0.008).
Conclusion: Fenofibrate use as a prophylactic therapy in full-term neonates with hyperbilirubinemia not reaching the level of phototherapy is well tolerated and associated with significant reduction of serum bilirubin levels, less need for phototherapy, and less need for hospital admission. Double dose treatment with Fenofibrate significantly lowered TSB with no significant increase in side effects but higher DROP of bilirubin when compared to single dose group.